Clinical Trial Overview
Objective: This study aimed to assess how effective and safe Buzhongyiqi pills (BZYQP) are in improving the appetite of colorectal cancer patients undergoing chemotherapy.
Trial Design
This was a pilot, randomized, single-blind cross-over clinical trial involving patients diagnosed with stage II-IV colorectal cancer receiving chemotherapy.
Methods
Participants were divided into two groups: one received BZYQP followed by a placebo, while the other received a placebo first, then BZYQP. Each group took ten pills three times daily. The study involved 12 visits to monitor their health before and after six chemotherapy cycles. Various questionnaires were used to evaluate appetite, quality of life, and drug safety.
Results
A total of 62 patients completed the trial. Key findings included:
- The BZYQP group showed significantly better appetite scores during the first three chemotherapy cycles.
- Patients taking BZYQP reported lower fatigue, appetite loss, and diarrhea symptoms compared to those on placebo.
- Fewer adverse effects were noted in the BZYQP group, especially in terms of nausea, vomiting, and anemia.
- No drug-related side effects were reported.
Conclusion
BZYQP is a safe and effective option for improving appetite in colorectal cancer patients undergoing chemotherapy, contributing to a better quality of life.
Practical Solutions and Value
Clinical trials are essential for developing safe treatments. To translate these findings into practice, our AI-driven platform, DocSym, consolidates clinical guidelines and research into an accessible resource for healthcare providers.
In today’s healthcare landscape, efficiency is vital. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine, enhancing patient care management.
By leveraging AI, clinics can streamline workflows, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
